CALCIMEDICA, INC.

Analyst Reco. CalciMedica, Inc. OTC Markets

Equities

CALC

US38942Q2021

Market Closed - OTC Markets Other stock markets 16:30:01 2024-07-16 EDT			5-day change	1st Jan Change
4.88 ^USD	+1.46%		+9.91%	+70.63%

07-10	Oppenheimer Raises CalciMedica's Price Target to $20 From $14, Outperform Rating Maintained	MT
07-09	CalciMedica Says First Person Dosed in Phase 2 Trial of Auxora to Treat Acute Kidney Injury	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Raises CalciMedica's Price Target to $20 From $14, Outperform Rating Maintained	07-10	MT
JonesTrading Initiates CalciMedica With Buy Rating, Price Target is $22	02-16	MT
HC Wainwright Starts Coverage on CalciMedica with Buy Rating, $20 Price Target	01-29	MT
EF Hutton Initiates CalciMedica With Buy Rating, $17 Price Target	23-06-20	MT
Wedbush Drops Coverage of Graybug Vision on Termination of GB-102 for Wet Age-Related Macular Degeneration, GB-401 for Primary Open-Angle Glaucoma	22-08-26	MT
Piper Sandler Adjusts Graybug Vision's Price Target to $2 From $4, Maintains Neutral Rating	22-05-19	MT
Cantor Fitzgerald Adjusts Graybug Vision Price Target to $4 From $6, Maintains Overweight Rating	22-03-10	MT
Wedbush Analyst Starts Graybug Vision at Neutral With $3 Price Target, Down From $4	21-12-15	MT
GRAYBUG VISION : Wedbush Adjusts Price Target on Graybug Vision to $4 From $8 on GB-102 Timeline Adjustments; Neutral Rating Kept	21-05-13	MT
GRAYBUG VISION : Cantor Fitzgerald Adjusts Price Target for Graybug Vision to $6 From $14, Maintains Overweight Rating	21-05-13	MT
GRAYBUG VISION : SVB Leerink Downgrades Graybug Vision to Market Perform From Outperform, Adjusts PT to $5 From $23	21-05-13	MT
GRAYBUG VISION : Needham Downgrades Graybug Vision to Hold from Buy	21-05-13	MT
GRAYBUG VISION : Wedbush Downgrades Graybug Vision to Neutral From Outperform on Mixed Results of Phase 2b Altissimo Study	21-03-09	MT
GRAYBUG VISION : SVB Leerink Adjusts Graybug Vision's Price Target to $23 from $45, Keeps Outperform Rating	21-03-09	MT
GRAYBUG VISION : Piper Sandler Downgrades Graybug Vision to Neutral From Overweight; Price Target is $10	21-03-09	MT
GRAYBUG VISION : Cantor Fitzgerald Starts Graybug Vision at Overweight With $42 Price Target	20-12-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer